Long noncoding RNAs in key cellular processes involved in aortic aneurysms.

Abstract

Aortic aneurysm (AA) is a complex and dangerous vascular disease, featuring progressive and irreversible vessel dilatation. AA is typically detected either by screening, or identified incidentally through imaging studies. To date, no effective pharmacological therapies have been identified for clinical AA management, and either endovascular repair or open surgery remains the only option capable of preventing aneurysm rupture. In recent years, multiple research groups have endeavored to both identify noncoding RNAs and to clarify their function in vascular diseases, including aneurysmal pathologies. Notably, the molecular roles of noncoding RNAs in AA development appear to vary significantly between thoracic aortic aneurysms (TAAs) and abdominal aortic aneurysms (AAAs). Some microRNAs (miRNA - a non-coding RNA subspecies) appear to contribute to AA pathophysiology, with some showing major potential for use as biomarkers or as therapeutic targets. Studies of long noncoding RNAs (lncRNAs) are more limited, and their specific contributions to disease development and progression largely remain unexplored. This review aims to summarize and discuss the most current data on lncRNAs and their mediation of AA pathophysiology.

• Authors: Zhi-Yuan Wu, Matthias Trenner, Reinier A Boon, Joshua M Spin, Lars Maegdefessel
• Journal: Atherosclerosis (Atherosclerosis) Vol. 292 Pg. 112-118 (01 2020) ISSN: 1879-1484 [Electronic] Ireland
• PMID: 31785492 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.

Chemical References

• RNA, Long Noncoding

Topics

• Aortic Aneurysm, Abdominal (etiology)
• Aortic Aneurysm, Thoracic (etiology)
• Humans
• RNA, Long Noncoding (physiology)